APA (7th ed.) Citation

Greil, R., Rischin, D., Harrington, K., Soulières, D., Tahara, M., de Castro, G., . . . Burtness, B. (2020). 915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals of Oncology, 31, S660. https://doi.org/10.1016/j.annonc.2020.08.1030

Chicago Style (17th ed.) Citation

Greil, R., et al. "915MO Long-term Outcomes from KEYNOTE-048: Pembrolizumab (pembro) Alone or with Chemotherapy (pembro+C) Vs EXTREME (E) as First-line (1L) Therapy for Recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)." Annals of Oncology 31 (2020): S660. https://doi.org/10.1016/j.annonc.2020.08.1030.

MLA (9th ed.) Citation

Greil, R., et al. "915MO Long-term Outcomes from KEYNOTE-048: Pembrolizumab (pembro) Alone or with Chemotherapy (pembro+C) Vs EXTREME (E) as First-line (1L) Therapy for Recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)." Annals of Oncology, vol. 31, 2020, p. S660, https://doi.org/10.1016/j.annonc.2020.08.1030.